Cost–effectiveness of lenalidomide in multiple myeloma

References

• Drayson MT, Augustson BM, Begum G et al. Survival from relapse and the influence of therapy. XIth International Myeloma Workshop Proceedings. Haematologica92(6 Suppl. 2), 173 (2007) (Abstract PO-665).
   Google Scholar
• Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood93(9), 3064–3073 (1999).
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA91(9), 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med.341(21), 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood98(2), 492–494 (2001).
   PubMed Web of Science ®Google Scholar
• Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum Phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk. Res.27(10), 909–914 (2003).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F et al. A systematic review of Phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol.132(5), 584–593 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol.20(21), 4319–4323 (2002).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia17(4), 775–779 (2003).
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol.21(1), 16–19 (2003).
   PubMed Web of Science ®Google Scholar
• Gay F, Hayman S, Lacy M et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood115(7), 1343–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Schey SA, Jones R, Streetly M. A Phase I study of a new immunomodulatory thalidomide analogue CC 4047 (Actimid) in patients with relapsed/refractory multiple myeloma. J. Clin. Oncol.22(16), 3269–3276 (2004).
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br. J. Haematol.141(1), 41–51 (2008).
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol.27(30), 5008–5014 (2009).
   PubMed Web of Science ®Google Scholar
• Lioznov M, El-Cheikh J Jr, Hoffmann F et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant.45(2), 349–353 (2009).
   PubMedGoogle Scholar
• LeBlanc R, Hideshima T, Catley LP et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood103(5), 1787–1790 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother.57(12), 1849–1859 (2008).
   PubMed Web of Science ®Google Scholar
• Song W, van der Vliet HJ, Tai YT et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin. Cancer Res.14(21), 6955–6962 (2008).
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother.58(7), 1033–1045 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia15(12), 1950–1961 (2001).
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Macdonald CD et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer87(10), 1166–1172 (2002).
   PubMed Web of Science ®Google Scholar
• Lentzsch S, LeBlanc R, Podar K et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia17(1), 41–44 (2003).
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol.163(1), 380–386 (1999).
   PubMed Web of Science ®Google Scholar
• Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol.130(1), 75–84 (2002).
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Ther.305(3), 1222–1232 (2003).
   PubMed Web of Science ®Google Scholar
• Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin. Biol. Ther.4(12), 1963–1970 (2004).
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc. Res.69(1–2), 56–63 (2005).
   PubMed Web of Science ®Google Scholar
• Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med.5(5), 582–585 (1999).
   PubMed Web of Science ®Google Scholar
• Payvandi F, Wu L, Haley M et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell. Immunol.230(2), 81–88 (2004).
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res.69(18), 7347–7356 (2009).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood100(9), 3063–3067 (2002).
   PubMed Web of Science ®Google Scholar
• Zangari MTG, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of Phase I study of lenalidomide for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood98(775A), (2001) (Abstract 3226).
   Google Scholar
• Richardson PG, Blood E, Mitsiades CS et al. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood108(10), 3458–3464 (2006).
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med.357(21), 2133–2142 (2007).
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med.357(21), 2123–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood106(13), 4050–4053 (2005).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol.11(1), 29–37 (2010).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Schey SA, Wu P et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br. J. Haematol.137(3), 268–269 (2007).
   PubMed Web of Science ®Google Scholar
• Knop S, Gerecke C, Liebisch P et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood113(18), 4137–4143 (2009).
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam MA et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann. Oncol.17(12), 1766–1771 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Falcone A et al. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin. Lymphoma Myeloma9(2), 145–150 (2009).
   PubMedGoogle Scholar
• Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood115(4), 834–845 (2010).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Cavenagh JD, Jackson GH. Position statement on the use of bortezomib in multiple myeloma. Int. J. Lab. Hematol.30(1), 1–10 (2008).
   PubMed Web of Science ®Google Scholar
• McCarthy DA, Macey MG, Streetly M, Schey SA, Brown KA. The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. Int. Immunopharmacol.6(7), 1194–1203 (2006).
   PubMedGoogle Scholar
• Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur. J. Cancer42(15), 2433–2453 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia22(2), 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Normand C. Measuring outcomes in palliative care: limitations of QALYs and the road to PalYs. J. Pain Symptom Manage.38(1), 27–31 (2009).
   PubMed Web of Science ®Google Scholar
• Higginson IJ, Foley KM. Palliative care: no longer a luxury but a necessity? J. Pain Symptom Manage.38(1), 1–3 (2009).
   PubMedGoogle Scholar
• Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J. Pain Symptom Manage.31(1), 58–69 (2006).
   PubMed Web of Science ®Google Scholar
• Higginson IJ, Costantini M. Dying with cancer, living well with advanced cancer. Eur. J. Cancer44(10), 1414–1424 (2008).
   PubMed Web of Science ®Google Scholar
• Koffman J, Morgan M, Edmonds P, Speck P, Higginson IJ. “I know he controls cancer”: the meanings of religion among Black Caribbean and White British patients with advanced cancer. Soc. Sci. Med.67(5), 780–789 (2008).
   PubMed Web of Science ®Google Scholar
• Higginson IJ, Donaldson N. Relationship between three palliative care outcome scales. Health Qual. Life Outcomes2, 68 (2004).
   PubMedGoogle Scholar
• Gomes B, Higginson IJ. Where people die (1974–2030): past trends, future projections and implications for care. Palliat. Med.22(1), 33–41 (2008).
   PubMed Web of Science ®Google Scholar
• McCrone P. Capturing the costs of end-of-life care: comparisons of multiple sclerosis, Parkinson’s disease, and dementia. J. Pain Symptom Manage.38(1), 62–67 (2009).
   PubMed Web of Science ®Google Scholar
• British National Formulary (BNF) (55th Edition). BMJ Group and RPS Publishing, London, UK (2009).
   Google Scholar
• Bonkowski JJ, Vermeulen LC, Kolesar JM. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. J. Oncol. Pharm. Pract. DOI: 0: 1078155209351967v1 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Douglas HR, Normand CE, Higginson IJ, Goodwin DM. A new approach to eliciting patients’ preferences for palliative day care: the choice experiment method. J. Pain Symptom Manage.29(5), 435–445 (2005).
   PubMed Web of Science ®Google Scholar
• Muhlbacher AC, Lincke HJ, Nubling M. Evaluating patients’ preferences for multiple myeloma therapy, a discrete-choice-experiment. Psychosoc. Med.5, Doc10 (2008).
   PubMedGoogle Scholar
• Cocks K, Cohen D, Wisloff F et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur. J. Cancer43(11), 1670–1678 (2007).
   PubMed Web of Science ®Google Scholar
• Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur. J. Haematol.83(4), 279–289 (2009).
   PubMed Web of Science ®Google Scholar
• King MT, Fayers PM. Making quality-of-life results more meaningful for clinicians. Lancet371(9614), 709–710 (2008).
   PubMed Web of Science ®Google Scholar
• Cook R. Introduction: multiple myeloma. J. Manag. Care Pharm.14(7 Suppl.), 4–6 (2008).
   PubMedGoogle Scholar